Muderrisoglu Ahmet, Babaoglu Elif, Korkmaz Elif Tugce, Ongun Mert C, Karabulut Erdem, Iskit Alper B, Emri Salih, Babaoglu Melih O
Department of Pharmacology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Department of Chest Diseases, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Front Genet. 2020 Nov 30;11:571997. doi: 10.3389/fgene.2020.571997. eCollection 2020.
To determine the effects of genetic polymorphisms of ABCB1 (MDR1), CYP2A6, CYP2B6 on smoking status, and clinical outcomes of smoking cessation therapies in a Turkish population.
130 smokers and 130 non-smokers were recruited. Individuals who never smoked were described as non-smokers. 130 smokers were treated with nicotine replacement therapy (NRT) ( = 40), bupropion ( = 47), bupropion + NRT ( = 15), and varenicline ( = 28). Smokers were checked by phone after 12 weeks of treatment whether they were able to quit smoking or not. Genotyping and phenotyping were performed.
Cessation rates were as follows; 20.0% for NRT, 29.8% for bupropion, 40.0% for bupropion + NRT, 57.1% for varenicline ( = 0.013). The frequency of ABCB1 haplotype was significantly higher in non-smokers as compared to smokers (21.5% vs. 10.8, respectively; = 0.018). Neither smoking status nor smoking cessation rates were associated with genetic variants of CYP2A6 ( = 0.652, = 0.328, respectively), or variants of CYP2B6 ( = 0.514, = 0.779, respectively).
Genetic variants of the drug transporter ABCB1 and the haplotype was significantly associated with non-smoking status. Neither ABCB1 nor CYP2A6, CYP2B6 genetic variants were associated with smoking cessation rates at the 12th week of drug treatment.
确定ABCB1（多药耐药蛋白1）、CYP2A6、CYP2B6基因多态性对土耳其人群吸烟状况及戒烟治疗临床结局的影响。
招募130名吸烟者和130名非吸烟者。从不吸烟的个体被描述为非吸烟者。130名吸烟者接受尼古丁替代疗法（NRT）（n = 40）、安非他酮（n = 47）、安非他酮+NRT（n = 15）和伐尼克兰（n = 28）治疗。治疗12周后通过电话检查吸烟者是否戒烟成功。进行基因分型和表型分析。
戒烟率如下：NRT为20.0%，安非他酮为29.8%，安非他酮+NRT为40.0%，伐尼克兰为57.1%（P = 0.013）。与吸烟者相比，非吸烟者中ABCB1 单倍型的频率显著更高（分别为21.5%和10.8%；P = 0.018）。吸烟状况和戒烟率均与CYP2A6的基因变异（分别为P = 0.652，P = 0.328）或CYP2B6的变异（分别为P = 0.514，P = 0.779）无关。
药物转运体ABCB1的基因变异和 单倍型与非吸烟状态显著相关。在药物治疗第12周时，ABCB1以及CYP2A6、CYP2B6的基因变异均与戒烟率无关。
